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Abstract
Head and neck squamous cell carcinoma (HNSCC) is a highly invasive cancer with a fiveyear overall survival of approximately 50%. HNSCC incidence is increasing in WV and other
Appalachian areas due to high tobacco consumption and human papilloma virus exposure.
Genomic instability is a hallmark of tobacco carcinogen exposure, resulting in amplification of
chromosomal region 11q13 in 25% of all HNSCC cases. 11q13 amplification correlates with
poorer prognosis and increased tumor aggressiveness. The CTTN locus resides in the 11q13
amplicon and encodes the actin-regulatory protein cortactin. Increased cortactin expression
resultant from CTTN amplification drives HNSCC invasiveness by increasing tumor cell migration
and invadopodia formation. Invadopodia are tumor cell membrane protrusions responsible for
degrading the basement membrane and stromal extracellular matrix (ECM) proteins, facilitating
regional tumor dissemination. Prior studies have demonstrated that loss of cortactin expression
by RNA interference blocks invadopodia formation, suggesting that cortactin is an essential
invadopodia protein. However, recent work from our group utilizing 3D in vitro and transgenic
knockout mouse models indicates that cortactin removal fails to block HNSCC invasion. The
purpose of this study is to unequivocally determine the role of cortactin in HNSCC invadopodia
function and tumor invasion using clustered regularly interspaced short palindromic repeat
(CRISPR)-Cas9 knockout technology in HNSCC cell lines. The overall hypothesis is that
HNSCC may have compensatory cortactin and/or invadopodia-independent mechanisms
capable of driving tumor invasiveness independent from cortactin. We have produced
multiple cortactin knockout HNSCC clonal cell lines using CRISPR-Cas9 that lack detectable
cortactin expression. HNSCC lines lacking cortactin form mature invadopodia and degrade ECM
to the same extent as cortactin-expressing control cells. In addition, cortactin knockout cells have
the same degree of invasiveness in 3D collagen-based tumor spheroid and organotypic models.
These

results

suggest

that

HNSCC

utilizes

one

or

more

cortactin-independent

alternative/compensatory mechanisms to generate invadopodia in order to maintain the capacity

for tumor cells to invade. Future work will identify these compensatory mechanisms as a first step
towards crafting effective anti-invasive therapies.
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Introduction
Overview of Head and Neck Squamous Cell Carcinoma
HNSCC is an invasive neoplasm arising from the stratified squamous epithelium that lines
the upper aerodigestive tract. In the United States, the annual incidence of HNSCC is 50,000
diagnoses with nearly 10,000 deaths. The annual incidence increases to over 600,000 diagnoses
globally1. An important characteristic of HNSCC is the ability of the primary tumor to invade and
destroy a diverse array of neighboring craniofacial structures. The destruction of these structures
often results in mechanical obstruction of organs and immense pain for the patient. Primary tumor
location in combination with the high degree of invasiveness endemic to HNSCC makes this
cancer type difficult to treat and manage at the clinical level (Fig. 1). In addition to loco-regional
invasion, HNSCC typically metastasizes to the spatially close cervical lymph nodes in the neck,
which is common in late stage disease and correlates clinically to poor patient outcomes 2,3. These
characteristics contribute to the high lethality observed in this disease.
Standard of care for HNSCC depends on tumor staging, which is determined by cervical
lymph node status in late stage cancer (defined by American Joint Committee on Cancer (AJCC)
as Stage III or IV). When possible, surgical
resection of the primary site and neck
dissection to remove residual disease even
in patients with negative cervical lymph
node involvement is typically combined with
pre- or post-surgical chemotherapy and
radiation. HNSCC has two FDA approved
targeted

therapies

that

provide

slight

Figure 1. Representative PET (positron emission
tomography) scan of a Stage IV HNSCC patient seen
at Ruby Memorial Hospital. White and yellow areas are
indicative of high metabolic activity. The primary tumor is
located in the floor of the mouth and exhibits extensive
invasion into the mandible and cervical lymph nodes.
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increases in patient survival when combined with conventional treatment 4,5. The first approved
therapy was Erbitux (cetuximab), a chimeric monoclonal antibody against epidermal growth factor
receptor (EGFR), inhibiting downstream tumor cell proliferation6. The second approved therapy
is Keytruda (pembrolizumab), a humanized monoclonal antibody against the programmed death
1 (PD-1) receptor on T-cells, preventing PD-1 interaction with programmed death-ligand 1 (PDL1)4. Even with advances in conventional treatment and these targeted therapies, five-year posttreatment survival has remained near 50% since 19907. The risk factors of greatest concern for
causing HNSCC include oral cavity infection with oncogenic serotypes of human papillomavirus
(HPV), alcohol consumption, and tobacco use8,9.
HNSCC caused by HPV infection (HPV+) is associated with increased patient survival
compared to patients that are HPV negative (HPV-) 9. This is due to the lower number of genomic
alterations present in HPV+ tumors, resulting in improved response to conventional therapies due
to less complex genetic landscapes and genetic heterogeneity in tumor initiating cells 10,11. HPV
infection causes HNSCC by inactivating TP53 and Rb tumor suppressors through viral
oncoproteins E6 and E710. Although HPV-driven HNSCC is an important subset within the
disease, HPV- HNSCC is the focus of this study due to this form having the worst patient survival
and increased tobacco-related genomic damage.
HPV- HNSCC and alcohol consumption are clearly associated12. However, the
mechanisms by which alcohol leads to HNSCC are still not fully understood. One proposed
mechanism is that the main metabolite of alcohol, acetaldehyde, causes genetic damage which
leads to oncogenic mutations13,14. Another possibility is a synergistic effect with tobacco use. Not
pure ethanol, but rather alcoholic drinks may increase the absorption of carcinogens within
tobacco products through the mucosa where HNSCC originates15. Other potential mechanisms
such as DNA damage directly caused by ethanol, alcoholic drinks causing nutritional deficiencies,
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and potential carcinogens other than ethanol
within alcoholic drinks have weaker evidence
for causing HNSCC16.
While alcohol has some association
with HNSCC, carcinogens within tobacco
products have a much stronger link as
causative agents. Tobacco byproducts cause
genomic instability in exposed epithelium, a risk
factor that can create tumors with increased
genomic

copy

nonsynonymous

number
gene

alterations
mutations11,17.

and
In

addition, these tumors tend to have increased
genetic intra-tumoral heterogeneity, which is
also associated with poorer outcome18. Genetic
damage and the associated genomic instability

Figure 2. Core distribution 11q13 amplicon genes
in HNSCC. Diagram of chromosome 11, showing the
11q13 amplified region and location of the 4 11q13
“Cores” in relation to 11q22.
The amplification
frequency of each core is derived from 530 TCGA
HNSCC cases (shadowed) and mapped to the specific
chromosomal subregion. Cortactin (CTTN) maps to
Core 2 within the amplicon.

results in genomic amplification and deletion of several chromosomal regions11,19. The most
frequently amplified genomic region in tobacco-positive HNSCC is chromosome 11q13, which
occurs in 25%-50% of all patients20. The genes within this amplicon are illustrated in Figure 2.
This amplification event corresponds with increased invasive disease, regional tissue
involvement, cervical lymph node metastasis, increased chance of recurrence, and diseasecaused mortality21. Within the 11q13 region is the CTTN gene, which encodes the actin-regulatory
protein cortactin22. 11q13 amplification often results in increased cortactin expression in HNSCC,
and has been shown to enhance tumor cell invasion in HNSCC and other cancer types 23–28 (Fig.
3).
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The role of cortactin in cancer invasion
Several cancer types and cells lines
have

demonstrated

overexpression

that

increases

cortactin
proteolytic-

mediated invasion without impacting primary
tumor growth29. Cortactin is a rod-shaped
protein with multiple domains that serves as
a convergence point for several signaling

Figure 3. CTTN amplification and overexpression
identifies patients with worse overall survival.
Kaplan-Meier survival analysis of 522 HNSCC patients
for CTTN amplification (A) and for mRNA overexpression
with z-scores >2.0 (B). Patient data was obtained from
The Cancer Genome Atlas (TCGA). p-values were
obtained using a log-rank test.

pathways that govern tumor cell motility30. The amino terminal (NTA) domain consists of a series
of acidic residues responsible for binding the actin related protein 2/3 (Arp2/3) complex. Arp2/3
binds to the sides of existing filamentous actin (F-actin) to nucleate production of new filaments,
creating F-actin networks with 70 degree branch points31. The NTA domain of cortactin is followed
by six complete and one incomplete 37 amino acid tandem repeats, with the fourth repeat
responsible for direct binding to F-actin32. The combined action of the NTA and 4th repeat allows
cortactin to stabilize Arp2/3-F-actin branch point junctions33, preventing F-actin network
breakdown essential for cellular movement and tumor invasion. Following the cortactin repeats
region is a proline-rich region containing serine and tyrosine residues that serve as
phosphorylation sites for multiple oncogenic kinases30. This region is followed by a distal Src
homology (SH)3 domain, which binds to proline-rich regions in multiple signaling proteins.
Phosphorylation of cortactin at S405 and S418 releases autoinhibition of the SH3 domain,
enabling binding to and activation of a variety of cytoskeletal regulatory molecules30.
Phosphorylation of cortactin at Y421, Y470, and Y486 creates docking sites for SH2 domaincontaining proteins, which in turn generate scaffolds for increased actin polymerization and
regulation25,34. The combined ability of cortactin to simultaneously interact with multiple actin-
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regulatory proteins essential to dynamic Factin regulation underscores the importance
of this protein as a central hub in invasionbased signal transduction.
Several studies in HNSCC and other
tumor cell types have shown that tumor cell

Figure 4. Schematic of invadopodia. Left. Diagram of
Invadopodia function. Left. Breaching of basement
membrane and underlying stroma is shown. Right. Key
proteins involved in invadopodia formation and function.

invasion is initiated by subcellular structures termed invadopodia. Invadopodia are F-actin-based
ventral protrusions that concentrate matrix metallopeptidases (MMPs) to cleave proteins in the
basement membrane that supports all epithelial cells (Fig 4). Breaching of the basement
membrane allows tumor cells to penetrate the underlying stroma and to spread to regional and
distant metastatic sites. Cortactin is a component of invadopodia, where it functions with several
other proteins to govern invadopodia formation and function. Reduction of cortactin expression in
HNSCC and other tumor types using RNA interference (RNAi) has clearly shown that cortactin
expression is essential for the formation and function of invadopodia35,36, supporting the
importance of cortactin as a structural component necessary for maintaining invadopodia integrity.
In addition, cortactin has been shown to regulate intracellular trafficking of exocytic vesicles and
ultimately secretion of exosomes, where internal cargo (including MMPs) is expelled outside of
the cell37.
Cortactin, F-actin, Arp2/3 complex, neural Wiskott-Aldrich syndrome protein (N-WASP),
and Tks5 are all invadopodia components.32,26. Although some of these proteins arrive during
different steps of the invadopodia maturation process, all are present in mature invadopodia and
required for ECM degradation26. There are four distinct steps in the invadopodia maturation
process: precursor assembly, actin polymerization, stabilization, and matrix degradation 25.
Cortactin, F-actin, Arp2/3, and N-WASP are components of invadopodia precursors and are
necessary for precursor assembly. Tks5 arrives during invadopodia stabilization and is required
5

for maturation25,26. Cortactin functions in invadopodia by binding and activating the Arp2/3
complex, which in turn induces polymerization and generation of the structural F-actin network
necessary for invadopodia formation and subsequent tumor cell motility32,38. N-WASP also
functions by activating Arp2/3 complex actin nucleation, and is a second driver of branched Factin filament production within invadopodia.39. Tks5 is necessary for the maturation of
invadopodia by stabilizing the network of cortactin, Arp2/3, N-WASP, and actin. 26. Consequently,
cells lacking Tks5 have mature invadopodia with shorter half-lives, but precursor assembly is not
affected. Once cortactin and N-WASP mediated F-actin polymerization begins in the second
stage of formation, matrix metallopeptidase 14 (MMP14) is recruited to forming invadopodia25.
MMP14 is a transmembrane protease that is retained in the invadopodia membrane. In addition
to recognizing and cleaving ECM substrates, MMP14 actives other MMPs (primarily MMP2 and
MMP9) to enhance overall ECM proteolysis39. MMP activation is the main driver for the final step
in invadopodia formation. In vitro and in vivo experimental evidence indicates that the ECM
degrading capability of invadopodia are required for basement membrane breakdown, stromal
invasion, and metastatic spread through the vasculature

27,29

. Animal models of tumor cell

invasion and metastasis support a role for cortactin in driving tumor invasion. Tail vein injection
of

breast

cancer

cells

with

cortactin

overexpression

show

increased

lung

colonization/metastasis40. Tumor cell lines with either ectopic cortactin overexpression or
overexpression due to 11q13 amplification show increased cell motility and invasion 28. HNSCC
xenograft models with cortactin overexpression in vivo exhibit increased tumor size, enhanced
proliferation, and increased vascularization while cortactin reduction had opposite effects 41. These
studies collectively suggest cortactin is a key regulator of tumor aggressiveness by enhancing
invasion and metastasis when overexpressed in cancer.
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The paradox- evidence for cortactin-independent HNSCC invasion
While it is apparent cortactin is critical in driving invadopodia-mediated invasiveness in
HNSCC, the data generated in the field to date has been obtained using 2D in vitro model systems
or 3D tumor implantation xenografts23,36,24. While valuable, these models do not faithfully
recapitulate the 3D environment or the complete orthotopic tumor microenvironment provided by
a genetically engineered mouse (GEM) model. Our laboratory has recently evaluated the role of
cortactin in a conditional knockout mouse model. The model utilizes a tissue-specific Cre/loxP
system where lox sites flanked exon 4 of cortactin (floxed exon 4). This system is based on a
bacteriophage protein (cre-recombinase) that recognizes a 34 base pair DNA sequence (loxP)
and is able to excise sequences flanked by loxP (floxed) sites from the genome 42. In this system,
tamoxifen administration induced cre-recombinase expression, which in turn excises exon 4 of
cortactin. Removal of exon 4 resulted in a frameshift mutation, causing genomic cortactin
knockout and loss of protein
expression in mice homozygous
for floxed cortactin alleles. Mice
with

conditional

homozygous

cortactin removal in the tongue
epithelium were subsequently
exposed to 4-quinoline-1-oxide
(4-NQO),
mimics

a
the

compound
DNA

that

damaging

effect of tobacco carcinogens43.
Mice
tumors

with

4-NQO-induced

lacking

cortactin

expression exhibited invasion

Figure 5. Carcinogen induced HNSCC does not require cortactin for
invasion. Transgenic mice with flox sites flanking cortactin were treated
with tamoxifen orally to conditionally knockout cortactin in the squamous
epithelium of the tongue. Mice were then treated with 4-NQO to induce
tumors. Following tumor onset tongues were excised, paraffin
embedded and formalin fixed. Hematoxylin & eosin (H&E) and
immunohistochemical (IHC) labels were used to visualize cytokeratin-14
(CK14) and cortactin. Note that stromal invasion was still evident in
tumors lacking cortactin expression.
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into the tongue stroma to the same fidelity and degree as tongue tumors retaining cortactin
expression (Fig 5). These data suggest that cortactin is not essential for HNSCC invasion in
physiomimetic settings, or that genetic compensation for chronic cortactin removal occurred in
these tumors to facilitate their competitively advantageous invasive properties. While caveats with
this system are possible (incomplete knockout allows expression in a subset of cells capable of
invasion), in vitro RNAi systems are also subject to incomplete cortactin removal, as evidenced
by the inability to completely prevent invadopodia-induced ECM degradation in a RNAi cortactin
knockdown setting24. Collectively these results point to the need for clarifying the requirement for
cortactin expression in promoting invasion in HNSCC patients.
Using CRISPR-Cas9 mediated cortactin knockout to clarify the role of cortactin in HNSCC
invasion
The goal of the present study is to unequivocally determine the role of cortactin in driving
HNSCC invasion. To answer this question in a cost and time effective manner relative to the use
of the GEM cortactin system, CRISPR-Cas9 gene editing technology was employed to mutate
the CTTN locus in two HNSCC cell lines, generating transcripts incapable of producing functional
cortactin protein. These CRISPR-Cas9 mediated cortactin knockout and control lines were used
to evaluate HNSCC invasive properties in multiple traditional and one newly developed assay.
CRISPR-Cas9 effectively works as an RNA guided nuclease to create double strand breaks in
DNA at precise targeted locations44. CRISPR-Cas9 vector systems are generated by combining
the CRISPR-RNA (crRNA) and trans-activating CRISPR RNA (tracrRNA) into what is termed a
guide RNA (gRNA)45,46. The gRNA normally contains a spacer component of the crRNA consisting
of 20 contiguous nucleotides complementary to a specific genomic target by RNA-DNA base
pairing44. These 20 contiguous nucleotides are designed to be specific to a desired target
sequence within the genome. When designed, the target sequence should be unique within the
genome so that cas9 will only cause DNA double strand breaks at the desired target site. However
8

this system has been shown to tolerate mismatches in the RNA-DNA base pairing and still cause
a double strand break47. The toleration of one or two base pair mismatches in the gRNA and an
off-target DNA sequence is what leads to off-target effects in the CRISPR-cas9 system. First, a
well-designed gRNA will have a very low number of predicted mismatched sequences within the
genome that it has the potential to pair with and lead to cas9 activity. Second, to control for these
potential off-target effects, two gRNAs with different sequences were designed which should have
different potential off-target DNA sequences. The goal then is to design gRNAs where offtargeting is not a concern. This is accomplished through the placement of mismatches within
predicted off-target sequences to ensure cas9 does not become activated. The number of
nucleotide mismatches that can be tolerated depend on three main factors. First is the location of
the mismatches; when they are located near the 5’ end of the gRNA they are usually more
tolerated48. Thus designed gRNAs with predicted off-target binding where the mismatches are
near the 5’ end should be avoided. Second is the location of the target sequence; this is highly
variable and its effects on tolerances are not well known. Third is if the mismatches are part of
the protospacer adjacent motif (PAM), these generally have very low tolerances49. This is because
the gRNA cannot target any 20 nucleotide sequence, it must be adjacent to a PAM or the Cas9
does not cause a double strand break. The existence of PAMs put some limitations on selecting
a gRNA but not much. For example the PAM for the CRISPR-Cas9 system is 3‘-NGG 44. Since it
is impossible to design a gRNA where there are not at least some predicted off-target DNA
sequences it may bind with, selecting gRNAs with the mismatches near the PAM are essential
for minimizing off-target effects.
Using a single vector CRISPR-Cas9 system, we generated cortactin knockout in two
human HNSCC cell lines using a gRNA targeting the cortactin antisense strand in exon 3 of the
coding region. A second gRNA targeting the sense strand in exon 3 was used to mutate the
cortactin locus in one cell line. These lines were assayed for HNSCC invasive properties with
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standard gelatin degradation and tumor spheroid assays. All cortactin knockout cells were able
to form mature, matrix degrading invadopodia to the same degree as control cells expressing
cas9 only (no gRNA cloned into the vector). Cortactin knockout did not impact the invasion of 3D
HNSCC spheroids embedded in native collagen I. In addition, a novel in vitro HNSCC organotypic
invasion system that effectively recapitulates the oral cavity and HNSCC tumor microenvironment
unambiguously determined that cortactin-null cells are capable of invading to the same extent as
HNSCC cells with cortactin expression. These results are in alignment with the GEM model data,
and importantly, provide evidence to support the presence of a compensatory cortactinindependent mechanism to ensure maintenance of HNSCC invasive properties in cases where
cortactin expression is lacking.

Results
Construction of cortactin-targeting lentiviral CRISPR vectors. Cortactin knockout cell lines
were produced by initially cloning guide DNA (gDNA) oligos into the lentiCRISPR v2 plasmid. 50,51.
The gDNA oligos 1 and 2 transcribe into gRNA1 and gRNA 2, respectively. Two unique gRNAs
were designed to control for off-target effects. The gDNA oligos 1 and 2 are complementary to
opposing strands; gDNA 1 targets the coding strand and gDNA 2 the non-coding strand of the
CTTN locus within the adjacent 250 base pair region downstream of the translational start site in
exon 3. Exon 1 and 2 of the CTTN locus transcribe the 5’-untranslated region of the cortactin
mRNA52. The gDNAs were cloned into the lentiCRISPR v2 vector by standard methods. Gel
electrophoresis analysis of each vector following restriction endonuclease digestion showed the
expected 25 base pair shift in mobility for each gDNA set, indicating correct cloning for each PCR
product from lentiCRISPR v2, verifying gDNA oligo insertion (Fig. 6A). PCR products were
sequenced to validate the gDNA sequence (Fig. 6B). Following maxiprep production of the final
plasmids, each successfully cloned vector was subjugated to an endonuclease digestion analysis
to ensure correctness of the vector prior to transfection (Fig. 6C). Double digestion with the
10

Figure 6. Representative construction of cortactin-targeting lentiviral CRISPR vectors. A. PCR products of
the gRNA insertion region for gRNA2 clones. Multiple PCR reactions of the same condition are shown. B.
Sequencing of the gRNA2 PCR product in (A). C. Endonuclease digests of the lentiCRISPR v2 vector containing
the gRNA2 sequence. Banding patterns individual and double digest conditions are indicated.

restriction endonucleases EcoRI and BamHI produced the predicted banding pattern and size for
correctly cloned vector.
Antibody-based screening of cortactin CRISPR HNSCC cells for clonal cortactin knockout.
Lentiviral production utilized the human kidney cell line 293T/17. Each CRISPR construct was cotransfected with VSV-G and PAX2 to produce replication incompetent lentiviral particles. Viruses
used for HNSCC cell line transduction were lentiCRISPR v2 vector only (gRNA not cloned into
vector), lentiCRISPR v2 gRNA1 (gRNA1 cloned into vector), or lentiCRISPR v2 gRNA2 (gRNA2
cloned into vector). Pools of the HNSCC cell lines OSC19 empty lentiCRISPR v2 vector (OSC19
EV), OSC19 gRNA1 (OSC19 G1), OSC19 gRNA2 (OSC19 G2), UMSCC1 lentiCRISPR empty v2
vector (UMSCC1 EV), UMSCC1 gRNA1 (UMSCC1 G1), and UMSCC1 gRNA2 (UMSCC1 G2)
were produced and selected with puromycin. Both HNSCC cell lines were transduced with empty
lentiCRISPR v2 vector to control for viral infection and cas9 expression (data not shown).
While other screening methods such as PCR and gel analysis are traditionally used for
identifying CRISPR-modified cell colonies with frameshift mutations53, we opted to use a
preliminary dot blot analysis followed by subsequent western blot analysis to identify cell colonies
with complete cortactin knockout54. While this method does not require a viral selection step,
puromycin resistant cells were selected for before clonal isolation of the transduced cells. Cells
were diluted to roughly 5-10 cells per well in a 96-well from the pools of each post-puromycin
selected HNSCC line. Once confluent, cells were trypsinized and approximately 90% each colony
11

was lysed for dot blot analysis. The
remaining

cell

preserved

for

population
further

was

expansion

following screening. All cell lysates were
evaluated for cortactin expression with
an anti-cortactin antibody. An antibody
against the non-related actin binding
protein fascin was used as an internal
control within individual lysates (Fig.
7A). Initial screening revealed varying
levels of cortactin expression across cell
colonies. Colonies with low cortactin
expression from first screenings were
presumed to be either clonal but with
incomplete

cortactin

knockout,

or

consisting of mixed populations of
complete cortactin knockout cells with
puromycin resistant cells continuing to

Figure 7. CRISPR-Cas9 knockout of cortactin expression in
HNSCC lines. A. Dot blot screening of putative cortactin knock
UMSCC1 and OSC19 HNSCC cells following stable CRISPRCas9 selection. Clones were obtained following limiting dilution;
red “Xs” indicate discarded clones due to insufficient detection
of the control protein (fascin). Red “O” indicate colonies that
were further screened by western blotting. Gold “O” denotes the
colony (OSC19 G2) expressing gRNA from target Set 2 that
was expanded for further analysis. B, C, and D. Western
blotting of stable CRISPR-Cas9 HNSCC cells. Cells obtained
through the screening process depicted in (A) were expanded
and evaluated with an anti-cortactin antibody (4F11) against the
cortactin protein segment encoded by exon 10 in B. An
additional anti-cortactin antibody evaluated cortactin
expression against C-terminal cortactin residues in (C). D. Antiβ-actin antibody blotting as a protein loading control.

express cortactin. The dot blot assay is
unable to distinguish between these two possibilities for colonies with low cortactin expression.
Cell lysates lacking any observable cortactin expression were considered putative knock out cell
colonies (red circles on Fig. 7A) and were analyzed further for loss of cortactin expression.
While Western blot analysis is lengthy and requires greater amounts of protein, it is more
specific and sensitive compared to the dot blot analysis. Western blot analysis was used for final
determination of successful cortactin knockout in each line. Importantly, in many of the putative
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knockout cell colonies determined by dot blotting, cortactin expression returned when colonies
were expanded to provide sufficient cell amounts for Western blot analysis. The colonies with the
lowest levels of cortactin expression following this expansion were further subjected to additional
rounds of dilution, re-isolation and expansion in order to obtain cell colonies with complete
knockout. Once clean cortactin knockouts were observed by Western blot analysis (Fig. 7B), they
were periodically reevaluated to ensure each line maintained homogenous cortactin knockout.
Using this approach, we were ultimately able to generate clones lacking detectible cortactin
expression for OSC19 G2, UMSCC1 G1, and UMSCC1 G2. A clonal OSC19 G1 (knockout with
gRNA1 in the OSC19 cell line) was not obtained in spite of multiple attempts.
Initial screening was conducted using a cortactin monoclonal antibody recognizing exon
10. Western blotting of control and cortactin knockout lines with an additional cortactin antibody
recognizing C-terminal residues also demonstrated complete cortactin knockout in each line,
indicating that a truncated protein using alternative start codons 3’ of the initiator codon was not
produced (Fig. 7C). In all cases, Western blotting of β-actin was completed with the same lysates
for control and cortactin knockout lines to ensure even protein concentrations between the lysates
(Fig. 7D). Homogenous cortactin knockout in each clone was further supported through
immunofluorescent labeling of cortactin control and knockout cell lines (Fig. 9).

Genomic

sequencing of each cortactin knockout cell line was attempted, and the results indicated that
mutations occurred in the CTTN locus for each line. However, the exact mutation in each line
remains unclear due to poor signal intensity of the sequence read for each cell line (data not
shown). This result suggests that each allele of CTTN underwent a unique mutation within the
same cell line.
HNSCC cells with cortactin knockout form functional invadopodia. Removal of cortactin
expression by RNAi has been shown to significantly reduce the number of invadopodia and matrix
degradation in multiple cell lines from different cancer types24,25. In SCC61 cells (a HNSCC cell
13

Figure 8. CRISPR-Cas9-mediated cortactin knockout in HNSCC does not impact invadopodia function. Left
UMSCC1 and OSC19 cells containing EV, G1 or G2 were evaluated for invadopodia formation and gelatin
degradation. Cells were plated on coverslips coated with fluorescent gelatin (pseudocolored white) for 12h, fixed
and immunofluorescent stained for the invadopodia markers F-actin (red) and Tks5 (blue). Arrows point to individual
invadopodia and corresponding regions of gelatin clearing (indicating areas of degradation). Right Normalized
gelatin degradation within F-actin labeled area, divided by the cell area (n=40; 4 independent experiments). Top.
OSC19 EV vs OSC19 G2 n.s.; p=0.12. Bottom. UMSCC1 EV vs UMSCC1 G1 n.s.; p=0.52. UMSCC1 EV vs
UMSCC1 G2 n.s.; p=0.64.

line), RNAi of cortactin reduced the population of invadopodia producing cells from 50% to 20% 24.
In MTLn3 cells (a rat breast cancer cell line), RNAi of cortactin reduced the population of cells
with invadopodia precursors from 24% to 6%. Additionally, the normalized degradation area in
these cells was reduced to 20% of control cells in both cases25. In both of these lines, residual
invadopodia and corresponding amounts of remaining gelatin degradation was observed with
RNAi. Incomplete removal of cortactin by RNAi was presumed to be the reason for residual
invadopodia formation and ECM degradation activity. Following this logic, cortactin knockout cells
14

then would be incapable of producing invadopodia or degrading gelatin. However, OSC19 and
UMSCC1

cells

with

CRISPR-mediated

cortactin

knockout

had

similar

numbers

of

invadopodia/cell and ECM degradation activity as control cells expressing empty lentiCRISPR v2
vector (Fig. 8). The complete lack of any effect on invadopodia numbers, invadopodia formation
and function in cortactin knock-out cells was surprising and unexpected, especially since these
lines have been shown to be sensitive to RNAi-mediated cortactin knockdown in previous
studies55.
While cortactin has been utilized as the prototypic marker for invadopodia, other proteins
have been used in conjunction with cortactin labeling to confirm invadopodia in tumor cells. To
this end, we utilized rhodamine phalloidin (for F-actin), NWASP, and Tks5 to identify the presence
of mature invadopodia26 in cells with and without cortactin expression. The co-localization of these
markers in cells with areas of gelatin degradation indicates fully formed and functional
invadopodia. Co-localization of these markers was observed in control cells and in all cell lines
lacking cortactin expression, suggesting that recruitment of additional proteins essential for
invadopodia formation and maturation are not impacted by complete lack of cortactin expression
(Fig. 8, 9).
Collective spheroid tumor invasion is not significantly altered by cortactin knockout.
Although invadopodia activity is deemed essential for initiating tumor invasion, the assay used to
measure invadopodia function does not measure cellular movement and thus, does not evaluate
downstream invasion per se. To determine if CRISPR-cas9 mediated cortactin knockout results
in decreased HNSCC invasion, 3D invasion assays were conducted using tumor spheroids
embedded in collagen I. OSC19 EV and G2 tumor spheroids were produced on noble agar and
layered onto collagen I, then covered by additional collagen to fully encase the spheroids. HNSCC
cells in this assay typically invade as a collective group from the spheroid over time in a planar
manner between the collagen layers56. Initial radii for spheroids in each cell line after embedding
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Figure 9. N-WASP localizes to invadopodia and areas of gelatin degradation in cortactin knockout HNSCC
cells. UMSCC1 and OSC19 cells containing EV, G1 or G2 were evaluated for invadopodia formation. UMSCC1
and OSC19 cells containing EV, G1 or G2 were evaluated for invadopodia formation and gelatin degradation. Cells
were plated on coverslips coated with fluorescent gelatin (pseudocolored white) for 12h, fixed and
immunofluorescent stained for the invadopodia markers F-actin (red), cortactin (green) and N-WASP (purple).
Arrows point to individual invadopodia and corresponding regions of gelatin clearing.

was recorded, then re-measured after 24 h. Mean invasive distances were calculated for each
cell line, with no significant difference observed between OSC19 EV (cortactin WT) and G2
(cortactin-null) cells (Fig. 10). These data indicate that genetic mutation of CTTN resulting in
cortactin knockout does not have an effect on HNSCC invasiveness, counter to the impact of
cortactin RNAi on invasion in other systems23,25.
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Cortactin
significantly

knockout

does

reduce

not

collective

invasion in an ex vivo model system.
To further assess the role of cortactin in
HNSCC invasion, we utilized a recently
developed ex vivo organotypic model of
collective tumor cell invasion used for
other

carcinomas

from

stratified

Figure 10. Cortactin knockout in HNSCC cells does not
alter collective invasion from tumor spheroids. Left.
Representative phase contrast images of OSC19 tumor
spheroids embedded in 2mg/ml native collagen I at the
indicated time points. Maximal invasive distance for each
tumor cell group is circled in grey. Right. Quantification of
invasive distances for each cell line from the tumor sphere
centroid (n= ≥14 spheroids; 3 independent experiments). n.s.;
p=0.23.

squamous epithelium57. In this model,
cancer associated fibroblasts organize and constrict a pseudo-stroma of collagen I and ECM
proteins provided by Matrigel. Tumor cells are layered on top of this stroma, and become stratified
as in the human disease when the culture is raised to the air-liquid interface. This presents a more
physiomimetic ECM and better copies the tumor microenvironment. OSC19 cells were observed
to be less invasive compared to UMSCC1 cells. However, both cell lines were capable creating
detached invasive groups into the pseudo-stroma (Fig. 11, 12). The degree of invasion in this
setting was measured using an objective algorithm designed to detect detached collective groups

Figure 11. Cortactin removal by CRISPR-Cas9 does not impair HNSCC invasion in organotypic cultures.
OSC19 EV and G2 cells were plated onto native collagen I containing primary HNSCC CAFs that mimic the
HNSCC microenvironment. Cells were allowed to invade for 10 days. White arrows illustrate detached invasive
groups. Blue arrows denote attached invasive strands. Cultures were harvested, fixed and labeled with
hematoxylin and eosin (left) and cytokeratin 14 by Immunofluorescence (middle). The invasion index (right) was
calculated as the number of detached groups x total area of detached groups x mean invasive depth (n=6; 2
independent experiments) n.s.; p=0.07.
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Figure 12. Cortactin removal by CRISPR-Cas9 does not impair HNSCC invasion in organotypic cultures.
UMSCC1 EV, G1, and G2 cells were evaluated for invasive properties as detailed in Figure 11 (n=6; 2 independent
experiments). UMSCC1 EV vs UMSCC1 G1 n.s.; p=0.19. UMSCC1 EV vs UMSCC1 G2 n.s.; p=0.50.

in the stroma, factoring in number, area and mean invasive depth of the detached groups in
random microscopic fields. This produces an independent invasion index for each line. No
statistical differences in any invasion index were calculated for the OSC19 G2, UMSCC1 G1 and
G2 cortactin-null lines compared to control. However, an interesting qualitative difference was
observed in the UMSCC1 cell lines compared to EV controls. UMSCC1 cortactin knock-out cells
had more extensive collective invasion with longer invasive strands that had yet to detach from
the overlying primary tumor cell layer (Fig. 12). This layer was excluded from quantitation, and
since these strands remained attached to the layer, they were also excluded in spite of the
qualitative appearance that cortactin knockout in both lines enhanced tumor invasion.

Discussion
This study set out to clearly determine the role of cortactin in HNSCC invadopodia function
and tumor invasion through CRISPR-cas9 mediated removal of cortactin expression. Published
literature supports cortactin as a protein that regulates cell motility and secretion of cargo through
governing cytoskeletal-based signaling. RNAi knockdowns and overexpression experiments
clearly show that cortactin expression levels regulate invadopodia number and ability to degrade
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an artificial ECM gelatin matrix. Yet when cortactin expression was removed at the genetic level
in the GEM model, invasion was not impacted as the prior literature would predict. This key piece
of data drove the thinking behind the hypothesis that HNSCC may have compensatory cortactin
and/or invadopodia-independent mechanisms capable of driving tumor invasiveness independent
from cortactin.
CRISPR-cas9 technology was chosen to address this hypothesis as it would remove the
potential for low levels of cortactin expression from incomplete RNAi or knockout to drive
invadopodia function and cellular invasion. The major critique of CRISPR-cas9 technology is the
potential for off-target effects. This was addressed by carefully considering the design of each
gRNA and using multiple gRNAs. If the gRNAs were producing different phenotypes, it would be
an indication of an off-target effect. This was not observed with either gRNA used in this study.
From a qualitative perspective, the proliferation and morphology of the cortactin knockout cells
remained identical to the control lines.
The first steps of generating cortactin knockout cell lines proved to be very efficient up to
the point of clonal selection. For context, gRNA design to transduction was completed within a
month compared to clonal selection which spanned over 8 months to produce the three cortactin
knockout cell lines used in this study. The difficultly with isolating cortactin knockout cells caused
us to question if the vector system was built correctly and if cas9 was active in transduced cells.
Ultimately, we concluded the difficulty we were experiencing in clonal isolation was due to the
nature of the cell lines we had chosen. HNSCC typically invades in collective groups and has not
undergone the epithelial to mesenchymal transition (EMT). OSC19 and UMSCC1 cells prefer to
grow in multicellular groups and tend to remain attached to each other after standard
trypsinization for cell passaging. Therefore, once pools of transduced cells were created, it
became quite difficult to get single cells into a well to be grown clonally. This was only achieved
once with the OSC19 G2 cell line, as it did not need to be re-isolated more than once to get a
19

homogenous knockout cell population. The other cell lines were shown to have very low levels of
cortactin expression after several rounds of near-limiting dilution, which was attributed to
puromycin-resistant cells that retained cortactin expression adhering to knockout cells within each
diluted clone. These cells were removed by re-isolating subpopulations of the cells until cortactin
expression was completely absent. It was obvious that these cells were not expressing cortactin
due to an incomplete knockout because upon immunofluorescence analysis of these cells, the
vast majority lacked cortactin expression. Also, cortactin expression did not reappear through
multiple passages of the cell lines, confirming that the population was homogenous for cells with
complete cortactin knockout.
The first experiment performed with these CRISPR-cas9 mediated cortactin knockout cells
was to delineate the mechanism by which cortactin-null cells in the GEM model used for invasion.
Prior literature couples cortactin to invadopodia very tightly, with one paper going as far to say
“cortactin is essential for invadopodia-associated ECM degradation” 24. Based on these studies,
we predicted that cortactin knockout would completely remove the ability of HNSCC cells to
produce invadopodia or degrade a gelatin matrix. We thought that since these data were collected
in a 2D assay, whereas the GEM model data was in vivo, that an alternative mechanism for
invasion existed that could not be observed/activated in the 2D in vitro model. However, upon
using the cortactin knockout cells in the same 2D in vitro gelatin degradation model, we were
surprised that these cells produced and degraded invadopodia to the same degree as the control
cells. Multiple invadopodia markers were used to confirm the co-localization of F-actin and gelatin
degradation was due to mature, fully functional invadopodia. In attempt to determine how these
cortactin independent invadopodia form and function, future studies looking at the morphology
and intensity of signal of these and other invadopodia markers may be revealing. This result
suggested that the GEM model HNSCC cells invaded using a compensatory mechanism with
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cortactin independent invadopodia, rather than an alternative invasion mechanism that is not
invadopodia driven.
The next goal was to further support the GEM model data with 3D invasion modeling. The
first model chosen to complete this was the 3D tumor spheroids embedded in native collagen I.
Prior use of the OSC19 cell line in tumor spheroids showed it to be more aggressive in this model,
and thus OSC19 G2 was used while the UMSCC1 cortactin knockouts were still being clonally
isolated. Once again no difference was observed in a model system where differences in invasive
distance were observed when RNAi was used on cortactin.
To closer recapitulate the GEM model and better physiomimic human HNSCC, the
organotypic model was developed for use with the OSC19 and UMSCC1 cell lines. This model
creates an organized collagen I/Matrigel pseudo-stroma which is presumably more difficult to
invade mechanically and proteolytically compared to the tumor spheroid model. With the addition
of human primary HNSCC cancer associated fibroblasts (CAFs) to this model, a key component
of the native microenviroment is restored that is not seen in other in vitro model systems.
Qualitatively, in the more invasive UMSCC1 cell lines in this model, cortactin knockout appears
to enhance collective invasion where prior literature would predict the opposite. However, when
quantitated with the invasion index, no significant difference was seen in either cell line. Thus,
through three different model systems with three cortactin knockouts generated by two unique
gRNAs in two cell lines, elimination of cortactin expression had no effect on HNSCC invasion.
These data fully support our observations in the cortactin knockout GEM model system.
A possible explanation for the results seen in this study is that clonal selection is the
underlying cause for cortactin-independent invadopodia formation and invasion. Studies
completed in breast and HNSCC cell lines with cortactin RNAi showed invadopodia number and
ECM degradation to be regulated by cortactin had residual invadopodia (25-40% of control
number) and ECM degradation (20% of control) in RNAi treated cells. The residual presence of
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invadopodia and gelatin degradation was attributed to incomplete removal of cortactin expression
by RNAi. These cells are assumed to retain cortactin expression below detection thresholds but
at a sufficient level to drive invadopodia formation. Under this assumption, cortactin is considered
an essential regulator for invadopodia formation and function25. However, if we instead assume
that the residual presence of invadopodia and gelatin degradation is attributed to a cortactinindependent invadopodia mechanism, then cortactin may not be an essential regulator for
invadopodia formation and function throughout the cell line population. This raises the possibility
that through clonal selection of the three cortactin knockout cell lines utilized in this present study,
that they were all part of the sub-population of cells that were already capable of producing
cortactin-independent invadopodia.
Considering the data from this study and in the field, genetic compensation is more likely
to be the driving force behind the retention of the invasive phenotype observed in cortactin
knockout cells. Mutations caused by direct genomic targeting tend to cause the upregulation of
genes that are not affected using transcriptional or translational interference58,59. One paper
comparing morpholino knockdown to knockout phenotypes in zebrafish found that 80% of the
phenotypes observed in knockdown were not reproduced by genomic knockout of the locus
responsible for generating the transcript for the same protein59. Morpholinos are DNA oligos that
bind with targeted mRNA to block translation and achieve knockdown. Another study looking
specifically at one protein found that morpholino or CRISPR interference (CRISPRi) knockdown
produced a vascular defect in zebrafish, while CRISPR-based knockout did not 58. CRISPRi
functions with a deactivated cas9 (dCas9) and inhibits gene transcription through blocking RNA
polymerase III without mutation of the gene. Proteomic analysis revealed that in zebrafish with
genomic knockout, another related protein through a common domain was upregulated to
mechanistically compensate for the vascular defect seen in the knockdown 58. These findings may
aid in clarifying the observed discrepancy in invasive behavior between cortactin knockout and

22

knockdown approaches within the same HNSCC cell lines. The current hypothesis for such
mutational-informed compensation is that the cell can sense a genetic mutation and activates
genes with redundant or similar function to compensate for the mutation, whereas the cell cannot
sense the removal of protein expression at the transcriptional or translation level. Thus a CRISPRcas9 mediated knockout of cortactin, inducing frameshift mutations in the CTTN locus, is sensed
by the HNSCC cells and a currently unidentified protein(s) may thus be upregulated to
compensate for loss of cortactin expression.
The cortactin knockout cell lines generated in this study thus provide the necessary
platform for future work to identify compensatory proteins upregulated to maintain invadopodia
formation and HNSCC invasion. RNA sequencing and/or proteomic analysis will be conducted in
efforts to identify unknown compensatory gene(s) products. An obvious candidate for
compensatory function is the cortactin homolog hematopoietic lineage cell-specific protein-1
(HS1). HS1 is not normally expressed in cells of epithelial origin such as HNSCC. HS1 has similar
domain organization and functions to cortactin in terms of binding F-actin and Arp2/3 60–62. To
determine if HS1 expression is upregulated in cortactin knockout HNSCC lines, we used the
human myeloma U266 cell line as a control for HS1 expression. This line expresses HS1 at high
levels compared to other screened myeloma
cell lines (data not shown). HS1 expression was
not observed in any parental, control or cortactin
knockout line (Fig. 13).
Therefore,

identifying

compensatory

proteins in cortactin knockout cells will be the
first step to identify alternative mechanisms of
invadopodia

formation

and

function

than

previously described in the field. Within the

Figure 13. HS1 does not compensate for loss of
cortactin. Western blotting of stable CRISPR-Cas9
HNSCC cells with anti-HS1. Lysates were probed
with an anti-β-actin antibody for even protein loading
levels. U266 myeloma cells were used as a positive
control for HS1 expression.
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completed experiments presented in this study, more data remains to be evaluated pertaining to
the immune-labeling of invadopodia markers to potentially hint towards the mechanism of
cortactin independent invadopodia/invasion. Effective multi-modal therapies can be further
developed as a result of simultaneous targeting of the cortactin pathway and the arising
compensatory mechanism to achieve the desired phenotypes observed in RNAi. This approach
could potentially be expanded to other promising pre-clinical data that failed in mice or in clinical
trials where an effect was seen in knockdown data. CRISPR-Cas9 technology would attempt to
reproduce knockdown data and when it fails to do so, additional mechanisms of compensation
could be discovered in a similar manner to increase future cancer treatment at the personalized
level.

Methods
Plasmid design
The lentiCRISPR v2 vector is a single vector CRISPR-Cas9 system which encodes the
inserted gRNA and cas9 to mediate genomic knockout as previously described53. The Aceview
program was used to identify the cortactin gene (CTTN) initiation codon with CTTN cDNA. A 250
base pair region adjacent to the start site was analyzed through the CRISPR design website at
the Massachusetts Institute of Technology to identify putative gRNA targets consisting of 20 base
pair sequences that were adjacent to an NGG, while minimizing off target effects in the human
genome. The top predicted gRNAs for successful knockout were scored by the inverse likelihood
of

off

target

binding.

We

selected

the

top

two

gRNAs:

CTTN

gRNA1

(5’-

ATGACGCGGGGGCCGATGAC-3’) scored a quality of 91/100 with 38 potential off target sites
(15 in genes) and CTTN gRNA2 (5’-ATCGGCCCCCGCGTCATCCT-3’) scored a quality of 89/100
with 41 potential off target sites (16 in genes). gDNA oligonucleotide pairs which transcribe into
the gRNA1 and gRNA2 target sequences were synthesized by Integrated DNA Technologies and
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sub-cloned into lentiCRISPR v2 as described50. Briefly, lentiviral vector digestion, oligo annealing,
and ligation was completed prior to transformation into Stbl3 bacteria. Ampicillin resistant clones
of Stbl3 bacteria were evaluated for transformation of plasmid containing either gDNA oligo 1 or
gDNA oligo 2. The DNA from the potential clones was isolated by plasmid miniprep using standard
procedures and verified by DNA sequencing for gDNA insertion into the vector. One correct
plasmid clone was selected for each CTTN-targeting gRNA (1 & 2) and expanded in Stbl3
bacteria. Maxipreps of each plasmid were completed using standard procedures. Each gRNAinserted vector was evaluated by BamHI/EcoRI restriction digest to confirm the presence of
gRNA1 and gRNA2 inserts, and used for subsequent lentiviral production.
Cell culture, transfection, and lentiviral infection
OSC19 and UMSCC1 cell lines were maintained in Dulbecco's modified Eagles medium
(DMEM) with 10% fetal bovine serum (FBS), and 1% penicillin-streptomycin.
The human kidney cell line 293T/17 was used to produce lentivirus particles for control
(empty lentiCRISPR v2 vector), CTTN gRNA1 and CTTN gRNA2. Transfection of the viral
components (vector, VSV-G, and PAX2) was conducted using calcium phosphate transfection.
18 micrograms of DNA were used per plate in 2M calcium chloride. After 20 min, 2X HEPES
buffered saline was added drop-wise to each plate while aerating the solution. Virus was
harvested over a period of 24-48h post-transfection.
Each virus (empty vector, gRNA1, and gRNA2) was used to transduce UMSCC1 and
OSC19 HNSCC cell lines at 40% confluence. Transduction proceeded for two days, then cells
were placed under puromycin selection (2 micrograms/mL) for 3-4 days, dependent on control
cell death.
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Clonal Selection
To rapidly screen each cell line with each gRNA construct, puromycin resistant cells for
each transduction condition (vector control, CTTN gRNA1 and gRNA2 in UMSCC1 and OSC19
cells) were diluted to 5-10 cells per well into a 96 well plate. Once confluent, the cells were
trypsinized and lysed for dot blot analysis as previously described 54. Briefly, cell lysate was added
directly to nitrocellulose and blotted for cortactin expression. Lysates without cortactin expression
were identified and the corresponding well of cells was expanded for western blot analysis as
previously described63. For cells that showed weak cortactin expression or the return of
expression in western blot analysis were limiting diluted and analyzed by dot blot up to three times
until knockout of cortactin expression was stable.
Antibodies for immunoblotting included anti-cortactin (1 μg/ml; 4F11) 23, anti-cortactin
(1:1000; ab68438; Abcam, Cambridge, MA, USA), anti-fascin 1 (1:1000; #sc-21743; Santa Cruz
Biotechnology, Santa Cruz, CA), anti-HS1 (1:1000; D83A8; Cell Signaling Technology, Danvers,
MA, USA), and anti-beta actin (1:1000; D6A8; Cell Signaling Technology, Danvers, MA, USA).
Fluorescent microscopy and gelatin degradation assay
Immunofluorescent labeling, microscopy, preparation of fluorescently-labeled gelatin
coated coverslips, ECM degradation assays, and quantitation were conducted as previously
described63,64. The specific method of quantitation performed was taking the degradation within
the cell area of the field divided by the cell area of the field (n=40; 4 independent experiments).
To identify invadopodia, cells were incubated with rhodamine-conjugated phalloidin (1:1000;
Invitrogen), anti-Tks5 (1:1,000; #sc-30122; Santa Cruz Biotechnology, Santa Cruz, CA)
graciously provided by Darren Seals, anti-cortactin monoclonal antibody 4F11 (1 μg/ml), and antiN-WASP (1:300; ab126626; Abcam, Cambridge, MA, USA).
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3-D spheroid invasion assay
Tumor spheroid formation and collagen I embedding was performed as previously
described56. In contrast, cells were not labeled for visualization and were observed with bright
field microscopy. Invasive distance was the difference measured in radii at 24 hours post
embedding into the collagen I substrate and initial length (n= ≥14 spheroids; 3 independent
experiments).
Organotypic culture
The protocol for the organotypic culture was completed as previously described 65 with
adaptations. Quantification of the organotypic culture was completed as previously described 66
with adaptations. The critical adaptation was optimization of cell number for both the HNSCC and
CAF cell lines. OSC19 cells were plated at 12.5 million per well with 500,000 CAFs. UMSCC1
cells were plated at 4 million per well with 500,000 CAFs. The quantification was performed using
ImageJ software in place of Optilab Pro software, Graftek.
To quantitate the invasion index in the organotypic model, antigen retrieval and fluorescent
labeling was performed on sectioned paraffin blocks. Sections dried overnight on charged slides.
The following day the slides were deparaffinized and rehydrated with pre-heated xylene (3x3
minutes), pre-heated ethanol (3x2 minutes), ethanol rinses (1x2 minutes of 95%, 80%, and 70%
ethanol each), rinsed in distilled water, and a wash in 1X Tris-buffered saline for five minutes.
Antigen retrieval was performed by heating citrate buffer to 98 C and incubating the slides for 20
minutes. Fluorescent labeling was performed as previously described63. Anti-cytokeratin 14
(prediluted; ab15462; Abcam, Cambridge, MA, USA) was used to distinguish the HNSCC cell
lines from CAFs in the collagen layer for the invasion index.
Imaging was completed on the Olympus VS120 slide scanning microscope. Image
analysis was completed with ImageJ. Three fields within the middle three fifths of each
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organotypic were used to quantitate the invasion index. A particle analysis of each image was
completed with the largest particle removed (the primary cell layer) for the number of invasive
groups and the total area of the invasive groups. A hull and circle analysis was performed on each
field and its height was measured in 5 areas across the highlighted region. This height was
averaged and multiplied together with the other two parameters to generate an invasion index
(n=6; 2 independent experiments)
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